Clinical Trial Update: A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis [Phase 2]

View source ↗

Summary

A Phase 2b trial evaluating the efficacy, safety, and tolerability of M1095 (Sonelokimab) in moderate to severe psoriasis has completed, with results posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• M1095 (Sonelokimab)

Snippet

Sponsor: Bond Avillion 2 Development LP | Conditions: Psoriasis | Phase 2 | Status: COMPLETED | Results posted: 2021-08-02